Aptevo Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
58.6%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$24.13next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Mipletamig Frontline AML Clinical Benefit Rate Quarterly87.0%Target: Phase 2 dose selection and trial completion
Mipletamig Frontline AML Complete Remission / Complete Remission with Incomplete Hematologic Recovery (CR/CRi) Rate Quarterly81.0%Target: Phase 2 dose selection and trial completion
Cash and Cash Equivalents Quarterly14.5MTarget: Maintain sufficient liquidity to fund operations
Watch Items
- RAINIER Trial Completion and Phase 2 Dose SelectionTrigger: Year-end 2026Action: Review clinical data package and prepare for Phase 2 trial initiation
- Standby Equity Purchase Agreement (SEPA) Drawdowns and Share DilutionTrigger: Significant increase in outstanding shares or downward pressure on stock priceAction: Monitor cash burn rate and evaluate non-dilutive funding alternatives
- Nasdaq Minimum Stockholders' Equity ComplianceTrigger: Stockholders' equity falling below $2,500,000Action: Execute compliance plan, which may include equity raises or strategic transactions
Research as of 20 Jun 2026